-biale.jpg){kind=logo}
12.00-12.10 |
prof. MACIEJ MAŁECKIJagiellonian University, Kraków, Poland
|
opening the international conference |
Chairmen of the Session nr I |
|
|
12.10-12.30 |
prof. GÖSTA GAHRTONKarolinska Institut, Sweden |
“History of treatment of multiple myeloma” |
12.30-12.40 |
discussion |
|
12.40-13.00 |
prof. HERMANN EINSELEUniversity Hospital of Wurzburg, Germany |
“CAR-T Cells in myeloma: current practice and future developments”
|
13.00-13.10 |
discussion |
|
13.10 13.30 |
prof. MORIE A.GERTZMayo Clinic, USA |
“Why high-risk smoldering multiple myeloma should not be treated Outside of a clinical trial” |
13.30-13.40 |
discussion |
|
13.40-14.00 |
prof. DAVID H. VESOLEHackensack University Medical Center, New Jersey Medical School,
|
“Bispecific T-cell engager therapy for multiple myeloma” |
14.00-14.15 |
discussion |
|
14.15-15.00 |
COFFE BREAK |
|
Chairmen of the Session nr II |
prof. Tomasz Sacha
|
|
15.00-15.20 |
prof. ARTUR JURCZYSZYNJagiellonian University, Kraków, Poland |
“Advances in supportive care for multiple myeloma in 2026”
|
15.20-15.30 |
discussion |
|
15.30-15.50 |
prof. ATTAYA SUVANNASANKHAIndiana University Melvin and Bren Simon Comprehensive Cancer Center, USA |
“Advances in systemic AL amyloidosis” |
15.50-16.00 |
discussion |
|
16.00-16.20 |
prof. JOSHUA RICHTERDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. |
“Practical aspects of immunotherapy in multiple myeloma” |
16.20-16.30 |
discussion |
|
16.30-16.50 |
prof. RAHUL BANERJEEFred Hutchinson Cancer Center, Seattle, USA |
"How I define and treat high - risk multiple myeloma” |
16.50-17.00 |
discussion | |
17.00-17.20 |
prof. LARYSA SANCHEZDepartament of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA Washington, Seattle, USA |
“How I treat fragile patients with multiple myeloma in 2026” |
17.20-17.30 |
discussion | |
17.30-17.50 |
prof. GHULAM REHMAN MOHYUDDINDivision of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA |
“Quality of life in multiple myeloma in 2026” |
